Education
About Us
Working with TipRanks
Follow Us
Luye Pharma Group Ltd. (HK:2186)
:2186
Total Valuation
Luye Pharma Group has a market cap or net worth of $14.49B. The enterprise value is HK$13.05B.
Market Cap$14.49B
Enterprise ValueHK$13.05B
Share Statistics
Luye Pharma Group has 3,761,670,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,761,670,700
Owned by Insiders33.13%
Owned by Institutions―
Financial Efficiency
Luye Pharma Group’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.34%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.34%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee1.18M
Profits Per Employee162.96K
Employee Count5,150
Asset Turnover0.20
Inventory Turnover2.21
Valuation Ratios
The current PE Ratio of Luye Pharma Group is 16.25. Luye Pharma Group’s PEG ratio is -1.34.
PE Ratio16.25
PS Ratio0.00
PB Ratio1.01
Price to Fair Value0.54
Price to FCF29.29
Price to Operating Cash Flow7.90
PEG Ratio-1.34
Income Statement
In the last 12 months, Luye Pharma Group had revenue of 6.06B and earned 471.89M in profits. Earnings per share was 0.13.
Revenue6.06B
Gross Profit4.04B
Operating Income1.15B
Pretax Income839.22M
Net Income471.89M
EBITDA1.79B
Earnings Per Share (EPS)0.13
Cash Flow
In the last 12 months, operating cash flow was -394.40M and capital expenditures 0.00, giving a free cash flow of -394.40M billion.
Operating Cash Flow-394.40M
Free Cash Flow-394.40M
Free Cash Flow per Share-0.10
Dividends & Yields
Luye Pharma Group pays an annual dividend of HK$0.059, resulting in a dividend yield of ―
Dividend Per ShareHK$0.059
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.88
52-Week Price Change35.17%
50-Day Moving Average2.25
200-Day Moving Average2.50
Relative Strength Index (RSI)90.75
Average Volume (3m)96.77M
Important Dates
Luye Pharma Group upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateMar 28, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend DateJun 29, 2020
Financial Position
Luye Pharma Group as a current ratio of 1.24, with Debt / Equity ratio of 67.22%
Current Ratio1.24
Quick Ratio1.15
Debt to Market Cap1.34
Net Debt to EBITDA3.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Luye Pharma Group has paid 194.21M in taxes.
Income Tax194.21M
Effective Tax Rate0.23
Enterprise Valuation
Luye Pharma Group EV to EBITDA ratio is 7.28, with an EV/FCF ratio of 0.00.
EV to Sales2.15
EV to EBITDA7.28
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Luye Pharma Group has $6.50B in cash and marketable securities with ¥10.32B in debt, giving a net cash position of $3.82B billion.
Cash & Marketable Securities$6.50B
Total Debt¥10.32B
Net Cash$3.82B
Net Cash Per Share$1.01
Tangible Book Value Per Share$2.17
Margins
Gross margin is 68.44%, with operating margin of 18.93%, and net profit margin of 7.79%.
Gross Margin68.44%
Operating Margin18.93%
Pretax Margin13.85%
Net Profit Margin7.79%
EBITDA Margin29.59%
EBIT Margin18.61%
Analyst Forecast
The average price target for Luye Pharma Group is $2.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.75
Price Target Upside-29.92% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-3.12%
EPS Growth Forecast-12.71%